Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International, Inc. (OTCBB: GCAN) today
announced that physicians from Tel Ha'Shomer Hospital in Tel Aviv, and
GammaCan will present top line findings of the GC 101 trial at the 5th
Annual Congress on Autoimmunity taking place in Sorrento Italy from
November 29th through December 3rd, 2006. The presentation and
abstract are titled "Efficacy and Safety of IVIG Intravenous
Immunoglobulin in Patients with Metastatic Melanoma." The senior
authors are Drs. Jacob Schachter, MD and Uriel Katz, MD, PhD and the
study was fully funded by GammaCan International, Inc.
The researchers will present phase II clinical data examining the
efficacy and safety of IVIG (GCAN101) in treating malignant, melanoma
obtained from nine patients with metastatic disease who had failed all
other modalities of therapy. Top line results suggest that IVIG may
lead to stabilization of the disease in some patients and that IVIG
therapy in patients with advanced malignant melanoma appears to be
safe.
Prof. Jacob Nusbacher, Director of Medical & Scientific Affairs at
GammaCan commented: "This study is part of our larger GCAN 101 open
label phase II study which also includes prostate and colon cancer
patients. Unlike most other anti-cancer agents, IVIG has an excellent
safety profile. Moreover, the results we see in melanoma are
encouraging, particularly when one considers the advanced state of
disease in the group of patients that were treated. These results give
us further impetus to develop VitiGam, our next generation
anti-melanoma immunoglobulin therapy."
Data from the colon and prostate cancer arms will be published
elsewhere.
About GCAN101
GCAN101 (standard IgG) is currently completing an open label, 30
patient phase II trial designed to evaluate the efficacy and safety of
IgG therapy in cancer patients who failed all current therapies. The
trial is enrolling patients with colon cancer, melanoma and prostate
cancer. The colon and melanoma arms are fully enrolled.
About GammaCan
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.